MetaVia Inc. Announces 1-for-11 Reverse Stock Split

Rhea-AI Summary

MetaVia (Nasdaq: MTVA) announced a 1-for-11 reverse stock split of its common stock, effective 5:00 p.m. ET on December 4, 2025, with trading on a split-adjusted basis beginning December 5, 2025.

The reverse split was authorized by stockholders June 30, 2025, and approved by the board at a 1-for-11 ratio to help the company comply with Nasdaq continued listing requirements. Outstanding shares will fall from approximately 25.4 million to 2.3 million, while the number of authorized shares remains 100 million. Conversion and exercise prices for restricted stock units, options and warrants will increase proportionally.

Any fractional shares will be rounded down and paid in cash based on the closing Nasdaq price on the last trading day before the split. The stock will continue to trade under the symbol MTVA and a new CUSIP will be 64132R503.

Positive

• Outstanding shares reduced from approximately 25.4M to 2.3M
• Authorized common shares remain at 100M
• Common stock will continue trading as MTVA on Nasdaq with a new CUSIP

Negative

• Conversion and exercise prices for RSUs, options and warrants will increase proportionally
• Fractional shares will be rounded down and paid in cash based on pre-split closing price
• Reverse split was implemented to comply with Nasdaq listing requirements, indicating prior listing risk

News Market Reaction

-20.07%

12 alerts

-20.07% News Effect

-13.2% Trough in 24 hr 47 min

-$5M Valuation Impact

$18M Market Cap

0.0x Rel. Volume

On the day this news was published, MTVA declined 20.07%, reflecting a significant negative market reaction. Argus tracked a trough of -13.2% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $18M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Reverse split ratio: 1-for-11 Par value per share: $0.001 Authorized shares: 100,000,000 shares +5 more

8 metrics

Reverse split ratio 1-for-11 Ratio for MetaVia common stock reverse split

Par value per share $0.001 Par value of MetaVia common stock

Authorized shares 100,000,000 shares Authorized common stock remains unchanged after split

Outstanding shares pre-split 25.4 million shares Approximate common shares outstanding before reverse split

Outstanding shares post-split 2.3 million shares Approximate common shares outstanding after reverse split

Effective time 5:00 p.m. ET, Dec 4, 2025 Time reverse stock split becomes effective

Split-adjusted trading date Dec 5, 2025 Date trading begins on a split-adjusted basis

New CUSIP 64132R 503 CUSIP number for common stock after reverse split

Market Reality Check

Price: $2.43 Vol: Volume 69,993 vs 20-day a...

low vol

$2.43 Last Close

Volume Volume 69,993 vs 20-day average 242,726 ahead of the reverse split news. low

Technical Price $8.56 is trading below the 200-day MA of $9.94 before the split.

Peers on Argus

MTVA was up 10.53% pre-announcement while high-affinity biotech peers like PRTG ...

MTVA was up 10.53% pre-announcement while high-affinity biotech peers like PRTG (-10.39%), THAR (-4.53%), LPCN (-3.34%), SYBX (-3.51%) and PULM (-1.98%) were all down, indicating stock-specific dynamics rather than a sector move.

Historical Context

5 past events · Latest: Dec 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 02	Reverse stock split	Neutral	-20.1%	Announced 1-for-11 reverse split to address Nasdaq listing requirements.
Nov 07	Clinical data update	Positive	+6.8%	Presented positive Phase 2a vanoglipel data in presumed MASH patients.
Nov 06	Earnings and update	Negative	-15.0%	Q3 2025 results with going-concern doubt and limited cash runway.
Nov 04	Conference presentation	Positive	+8.0%	Shared Phase 1 and preclinical DA-1726 data showing weight loss and safety.
Oct 27	Conference poster news	Neutral	-1.4%	Announced upcoming vanoglipel poster presentation at liver meeting.

Pattern Detected

Positive clinical and data-focused releases have coincided with gains, while structural or neutral items like regulatory updates and the reverse split announcement have seen negative reactions.

Recent Company History

Over recent months, MetaVia combined clinical progress with financing and listing-compliance actions. Positive data on vanoglipel and DA-1726 around Nov 4–7, 2025 coincided with price gains of 6.85% and 8%. By contrast, Q3 results on Nov 6, 2025, which highlighted going-concern risk and liquidity measures, saw a -15% reaction. Earlier poster and conference announcements had mixed responses. The Dec 2, 2025 reverse stock split news preceded a -20.07% move, underscoring sensitivity to capital-structure changes.

Market Pulse Summary

The stock dropped -20.1% in the session following this news. A negative reaction despite the mechani...

Analysis

The stock dropped -20.1% in the session following this news. A negative reaction despite the mechanical nature of a reverse split would fit prior instances where structural announcements drew selling pressure. The 1-for-11 action cuts outstanding shares from roughly 25.4 million to 2.3 million but leaves authorization at 100 million, so ownership percentages adjust accordingly. Historical data, including a -20.07% move after this announcement, highlights that investors often treated such steps cautiously.

Key Terms

reverse stock split, par value, nasdaq capital market, certificate of incorporation, +4 more

8 terms

reverse stock split financial

"today announced a 1-for-11 reverse stock split of its common stock"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

par value financial

"reverse stock split of its common stock, par value $0.001"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

nasdaq capital market regulatory

"the common stock will trade on The Nasdaq Capital Market ("Nasdaq")"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

certificate of incorporation regulatory

"to amend the Company's Third Amended and Restated Certificate of Incorporation"

A certificate of incorporation is an official government document that creates a corporation and records key facts such as its legal name, basic governance structure, and stock authorization—think of it as a company's birth certificate plus its basic rulebook. Investors care because it establishes the company’s legal existence, limits owners’ personal liability, and sets the framework for issuing shares and enforcing shareholder rights, which affects ownership, control and the company’s ability to raise capital.

restricted stock units financial

"issuable upon the conversion of the Company's outstanding restricted stock units, stock options"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock options financial

"issuable upon the conversion of the Company's outstanding restricted stock units, stock options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

warrants financial

"stock options and warrants in proportion to the ratio of the reverse split"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

cusip technical

"The new CUSIP number for the common stock following the reverse split is 64132R 503"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia" or the "Company"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a 1-for-11 reverse stock split of its common stock, par value $0.001 ("common stock"), effective at 5:00 p.m. Eastern Time on December 4, 2025.  Beginning on December 5, 2025, the common stock will trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis.

At the Company's annual meeting of stockholders on June 30, 2025, the stockholders approved a proposal to amend the Company's Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse split of the Company's outstanding common stock at a ratio in the range of 1-for-5 to 1-for-30 to be determined at the discretion of the Company's Board of Directors, whereby each outstanding 5 to 30 shares would be combined, converted and changed into one share of common stock, to enable the Company to comply with the Nasdaq's continued listing requirements. Subsequently, the Company's Board of Directors approved the reverse split at a ratio of 1-for-11. As a result of the reverse stock split, every 11 shares of the Company's common stock issued and outstanding will be automatically converted into one share of common stock, with no change in the $0.001 par value per share or authorized number of shares of common stock.

Upon effectiveness, the reverse stock split will cause a reduction in the number of shares of common stock outstanding and issuable upon the conversion of the Company's outstanding restricted stock units, stock options and warrants in proportion to the ratio of the reverse split, and will cause a proportionate increase in the conversion and exercise prices of such stock options and warrants. Any fraction of a share of common stock that would be created as a result of the reverse stock split will be rounded down to the next whole share and the stockholder will receive cash equal to the market value of the fractional share, determined by multiplying such fraction by the closing sales price of the Company's common stock as reported on Nasdaq on the last trading day before the reverse stock split becomes effective (on a split-adjusted basis).

The Company's common stock will continue to trade on Nasdaq under the symbol "MTVA." The new CUSIP number for the common stock following the reverse split is 64132R 503.

The number of authorized shares of the Company's common stock will remain at 100 million, while the number of outstanding shares will be reduced from approximately 25.4 million to approximately 2.3 million.

Additional information about the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission on June 10, 2025, a copy of which is also available on the Company's website under the Investors & News page.

About MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com. 

Forward Looking Statements

Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements, which include, among other statements, statements regarding the expected effective date of the reverse stock split and the expected date that the shares of common stock will begin trading on Nasdaq on a post-split basis. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's ability to execute on its commercial strategy; MetaVia's expectations regarding the sufficiency of its existing cash on hand to fund MetaVia's operations; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to MetaVia's stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-inc-announces-1-for-11-reverse-stock-split-302630216.html

SOURCE MetaVia Inc.

FAQ

What is the effective date of MetaVia's 1-for-11 reverse stock split (MTVA)?

The reverse split is effective at 5:00 p.m. ET on December 4, 2025, with split-adjusted trading beginning December 5, 2025.

How many MetaVia (MTVA) shares will be outstanding after the reverse split?

Outstanding shares are expected to decrease from approximately 25.4 million to about 2.3 million following the 1-for-11 split.

Will MetaVia's stock symbol change after the reverse split (MTVA)?

No, the company will continue to trade on Nasdaq under the symbol MTVA; a new CUSIP will be 64132R503.

How will MetaVia's reverse split affect options, warrants and RSUs?

Conversion and exercise prices for restricted stock units, options and warrants will be increased proportionally to the 1-for-11 ratio.

What happens to fractional MetaVia (MTVA) shares created by the reverse split?

Any fractional share will be rounded down and the holder will receive cash equal to the fractional portion multiplied by the closing Nasdaq price on the last trading day before the split.

Why did MetaVia (MTVA) implement the reverse stock split?

The board approved the 1-for-11 reverse split to enable the company to comply with Nasdaq's continued listing requirements after stockholder authorization.